Literature DB >> 8751083

Electrophysiological analysis of the actions of pituitary adenylyl cyclase activating peptide in the taenia of the guinea-pig caecum.

K McConalogue1, D J Lyster, J B Furness.   

Abstract

The actions of pituitary adenylyl cyclase activating peptide (PACAP) on membrane potential and conductance were investigated in the taenia of the guinea-pig caecum. The possible role of PACAP in inhibitory transmission was also investigated. Membrane potentials of smooth muscle cells were measured by intracellular microelectrodes, in the presence of hyoscine and nifidepine (both 10(-6)M. To determine conductance changes, current was passed from external plate electrodes using the technique of Abe and Tomita (1968). PACAP-27 caused a concentration dependent hyperpolarization of the muscle with a maximum of 12-15 mV at 10(-6)M. The hyperpolarization caused by PACAP was associated with a substantial increase in membrane conductance. The hyperpolarization was abolished by apamin (10(-6)M), a blocker of small conductance, calcium-dependent, potassium channels, and was reduced to about 50% by suramin (10(-4)M), which is an antagonist of P2 receptors for purines. The hyperpolarization was not reduced by tetrodotoxin (2 x 10(-6)M), suggesting PACAP acts directly on the muscle. With continued exposure to PACAP, the hyperpolarization decayed back to resting membrane potential after several minutes, possibly due to receptor desensitization. Inhibitory junction potentials (IJPs) were markedly reduced in amplitude in the period of presumed receptor desensitization to PACAP, were abolished by tetrodotoxin, but were not affected by suramin. Apamin abolished the IJP and revealed a small excitatory junction potential. This study implies that PACAP released from nerve fibres in the taenia caeci hyperpolarizes the muscle via an opening of apamin-sensitive potassium channels. The action is probably through type I PACAP receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751083     DOI: 10.1007/bf00169388

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  32 in total

Review 1.  Recent research on the biological activity of suramin.

Authors:  T E Voogd; E L Vansterkenburg; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

2.  Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut.

Authors:  F Sundler; E Ekblad; A Absood; R Håkanson; K Köves; A Arimura
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

3.  Identification of muscarinic M2 receptors on single muscle cells of the human and guinea pig intestine.

Authors:  J R Grider; K N Bitar; G M Makhlouf
Journal:  Gastroenterology       Date:  1987-11       Impact factor: 22.682

4.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

5.  [Effect of strychnine, hydrastine and apamin on synaptic transmission in smooth muscle cells].

Authors:  I A Vladimirova; M F Shuba
Journal:  Neirofiziologiia       Date:  1978

Review 6.  Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission.

Authors:  M J Rand
Journal:  Clin Exp Pharmacol Physiol       Date:  1992-03       Impact factor: 2.557

7.  Effect of apamin on release of vasoactive intestinal polypeptide (VIP) from the cat intestines.

Authors:  A Sjöqvist; J Fahrenkrug; M Jodal; O Lundgren
Journal:  Acta Physiol Scand       Date:  1983-09

8.  Inhibitory transmission in tenia coli mediated by distinct vasoactive intestinal peptide and apamin-sensitive pituitary adenylate cyclase activating peptide receptors.

Authors:  J G Jin; S Katsoulis; W E Schmidt; J R Grider
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

9.  The effects of vasoactive intestinal polypeptide on the electrical activity of guinea-pig intestinal smooth muscle.

Authors:  J M Hills; C S Collis; G Burnstock
Journal:  Eur J Pharmacol       Date:  1983-04-08       Impact factor: 4.432

10.  Regulation of the descending relaxation phase of intestinal peristalsis by PACAP.

Authors:  J R Grider; S Katsoulis; W E Schmidt; J G Jin
Journal:  J Auton Nerv Syst       Date:  1994-12-15
View more
  6 in total

1.  Purinergic mechanisms in the control of gastrointestinal motility.

Authors:  J C Bornstein
Journal:  Purinergic Signal       Date:  2007-10-06       Impact factor: 3.765

2.  Stimulant action of pituitary adenylate cyclase-activating peptide on normal and drug-compromised peristalsis in the guinea-pig intestine.

Authors:  A Heinemann; P Holzer
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Apamin- and nitric oxide-sensitive biphasic non-adrenergic non-cholinergic inhibitory junction potentials in the rat anococcygeus muscle.

Authors:  S Selemidis; J Ziogas; T M Cocks
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

4.  Tyrosine kinase involvement in apamin-sensitive inhibitory responses of rat distal colon.

Authors:  T Takeuchi; M Kishi; N Hirayama; M Yamaji; T Ishii; H Nishio; F Hata; T Takewaki
Journal:  J Physiol       Date:  1999-01-01       Impact factor: 5.182

5.  Analysis of contributions of acetylcholine and tachykinins to neuro-neuronal transmission in motility reflexes in the guinea-pig ileum.

Authors:  P J Johnson; J C Bornstein; S Y Yuan; J B Furness
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

6.  Pituitary Adenylate Cyclase-activating Polypeptide Inhibits Pacemaker Activity of Colonic Interstitial Cells of Cajal.

Authors:  Mei Jin Wu; Keun Hong Kee; Jisun Na; Seok Won Kim; Youin Bae; Dong Hoon Shin; Seok Choi; Jae Yeoul Jun; Han-Seong Jeong; Jong-Seong Park
Journal:  Korean J Physiol Pharmacol       Date:  2015-08-20       Impact factor: 2.016

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.